{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:51:28Z","timestamp":1792799488664,"version":"4.5.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019590","name":"CARB-X","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"US Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50122C00028"],"award-info":[{"award-number":["75A50122C00028"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT224842"],"award-info":[{"award-number":["WT224842"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Federal Republic of Germany"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is an unmet need for developing drugs for the treatment of gonorrhea due to rapidly evolving resistance of Neisseria gonorrhoeae against antimicrobial drugs used for empiric therapy, an increase in globally reported multidrug-resistant cases, and the limited available therapeutic options. Furthermore, few drugs are under development. Development of antimicrobials is hampered by challenges in clinical trial design, limitations of available diagnostics, changes in and varying standards of care, lack of robust animal models, and clinically relevant pharmacodynamic targets. On 23 April 2021, the US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institute of Allergy and Infectious Diseases of the National Institutes of Health co-sponsored a workshop with stakeholders from academia, industry, and regulatory agencies to discuss the challenges and strategies, including potential collaborations and incentives, to facilitate the development of drugs for the treatment of gonorrhea. This article provides a summary of that workshop.<\/jats:p>","DOI":"10.1093\/cid\/ciae386","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T21:53:10Z","timestamp":1721857990000},"page":"1201-1208","source":"Crossref","is-referenced-by-count":9,"title":["US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary\u2014Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea"],"prefix":"10.1093","volume":"81","author":[{"given":"Hiwot","family":"Hiruy","sequence":"first","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring , Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukal","family":"Bala","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring , Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Byrne","sequence":"additional","affiliation":[{"name":"Office of Infectious Diseases, Office of New Drugs, CDER, FDA , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerian Grande","family":"Roche","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring , Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong H","family":"Jang","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring , Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumathi","family":"Nambiar","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring , Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Rubin","sequence":"additional","affiliation":[{"name":"Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, CDER, FDA , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Yasinskaya","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring , Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Division of STD Prevention, National Center for HIV\/AIDs, Viral Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC) , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Division of STD Prevention, NCHHSTP, CDC , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Botgros","sequence":"additional","affiliation":[{"name":"Office of Biological Health Threats and Vaccines Strategy, Clinical Studies and Manufacturing Task Force, European Medicines Agency , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Cammarata","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Melinta Therapeutics , Parsippany, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo L","family":"Chaves","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Debiopharm International SA , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn D","family":"Deal","sequence":"additional","affiliation":[{"name":"Enteric and Sexually Transmitted Infections Branch, Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L","family":"Drusano","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida , Lake Nona, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M","family":"Duffy","sequence":"additional","affiliation":[{"name":"Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Boston University , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E","family":"Eakin","sequence":"additional","affiliation":[{"name":"Office of Biodefense, Research Resources & Translational Research, DMID, NIAID, NIH , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Gelone","sequence":"additional","affiliation":[{"name":"Office of the President - Clinical Research and Development, Nabriva Therapeutics plc , Fort Washington, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hiltke","sequence":"additional","affiliation":[{"name":"Enteric and Sexually Transmitted Infections Branch, DMID, NIAID, NIH , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Edward W","family":"Hook","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E","family":"Jerse","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Uniformed Services University , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice J","family":"McNeil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section on Infectious Diseases, Wake Forest University School of Medicine, Southeast STD\/HIV PTC, Forsyth County Department of Public Health, and North Carolina Strengthening the United States Response to Resistant Gonorrhea , Winston-Salem, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Newman","sequence":"additional","affiliation":[{"name":"Enteric and Sexually Transmitted Infections Branch, DMID, NIAID, NIH , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seamus","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Director- Research and Development, Global Antibiotic Research & Development Partnership , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Perry","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Early Programs, GlaxoSmithKline , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary E L","family":"Reno","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine in St. Louis, St. Louis STD\/HIV Prevention Training Center, St. Louis STI Regional Response Coalition , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul A","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Division of STD Prevention, NCHHSTP, CDC , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Sato","sequence":"additional","affiliation":[{"name":"Office of International Programs, Pharmaceuticals and Medical Devices Agency (PMDA) , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[{"name":"World Health Organization (WHO) Collaborating Centre for Gonorrhea and Other STIs, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora E C","family":"Wi","sequence":"additional","affiliation":[{"name":"Global HIV, Hepatitis and STIs Programmes, WHO , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Workowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme A","family":"O\u2019May","sequence":"additional","affiliation":[{"name":"DRT Strategies, Inc , Arlington, Virginia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita J","family":"Shukla","sequence":"additional","affiliation":[{"name":"Office of Infectious Diseases, Office of New Drugs, CDER, FDA , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Farley","sequence":"additional","affiliation":[{"name":"Office of Infectious Diseases, Office of New Drugs, CDER, FDA , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"2026071507262829000_ciae386-B1","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","article-title":"Update to CDC's treatment guidelines for gonococcal infection, 2020","volume":"69","author":"St Cyr","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026071507262829000_ciae386-B2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1071\/SH19023","article-title":"World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts","volume":"16","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"key":"2026071507262829000_ciae386-B3","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study","volume":"2","author":"Unemo","year":"2021","journal-title":"Lancet Microbe"},{"key":"2026071507262829000_ciae386-B4","year":"2012"},{"key":"2026071507262829000_ciae386-B5","year":"2016"},{"key":"2026071507262829000_ciae386-B6","author":"US Food and Drug Administration"},{"key":"2026071507262829000_ciae386-B7","author":"Bennet M, Young T, Doyle M, Ferguson D."},{"key":"2026071507262829000_ciae386-B8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciab071","article-title":"The duration of pharyngeal gonorrhea: a natural history study","volume":"73","author":"Barbee","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026071507262829000_ciae386-B9","article-title":"World Health Organization"},{"key":"2026071507262829000_ciae386-B10","author":"Pham"},{"key":"2026071507262829000_ciae386-B11","author":"Centers for Disease Control and Prevention"},{"key":"2026071507262829000_ciae386-B12","doi-asserted-by":"crossref","first-page":"e624","DOI":"10.1093\/cid\/ciaa293","article-title":"Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations, and symptom resolution following treatment of urethritis","volume":"71","author":"Bachmann","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5):","key":"2026071507262829000_ciae386-B13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/cid\/ciab153","article-title":"Doxycycline versus azithromycin for the treatment of rectal chlamydia in men who have sex with men: a randomized controlled trial","volume":"73","author":"Dombrowski","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026071507262829000_ciae386-B14","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/cid\/ciz1060","article-title":"International spread of multidrug-resistant Campylobacter coli in men who have sex with men in Washington State and Quebec, 2015\u20132018","volume":"71","author":"Greninger","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026071507262829000_ciae386-B15","doi-asserted-by":"crossref","first-page":"e01679-18","DOI":"10.1128\/AAC.01679-18","article-title":"Genetic mechanisms behind the spread of reduced susceptibility to azithromycin in Shigella strains isolated from men who have sex with men in Quebec, Canada","volume":"63","author":"Yousfi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071507262829000_ciae386-B16","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2002606","article-title":"Macrolide and nonmacrolide resistance with mass azithromycin distribution","volume":"383","author":"Doan","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071507262829000_ciae386-B17","doi-asserted-by":"crossref","first-page":"e01644-18","DOI":"10.1128\/AAC.01644-18","article-title":"Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model","volume":"63","author":"Connolly","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071507262829000_ciae386-B18","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/jac\/dky548","article-title":"Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review","volume":"74","author":"Kong","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026071507262829000_ciae386-B19","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1473-3099(20)30171-7","article-title":"Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction","volume":"20","author":"Se\u00f1a","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026071507262829000_ciae386-B20","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.cmi.2020.08.006","article-title":"Pharmacokinetic\/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea","volume":"26","author":"Theuretzbacher","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026071507262829000_ciae386-B21","first-page":"2","article-title":"The hollow fiber infection model: principles and practice","volume":"1","author":"Cadwell","year":"2015","journal-title":"Adv Antibiotics Antibodies"},{"key":"2026071507262829000_ciae386-B22","doi-asserted-by":"crossref","first-page":"e00521-20","DOI":"10.1128\/AAC.00521-20","article-title":"Relationship between gepotidacin exposure and prevention of on-therapy resistance amplification in a Neisseria gonorrhoeae hollow-fiber in vitro infection model","volume":"64","author":"Van Scoy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071507262829000_ciae386-B23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fmicb.2011.00107","article-title":"Estradiol-treated female mice as surrogate hosts for Neisseria gonorrhoeae genital tract infections","volume":"2","author":"Jerse","year":"2011","journal-title":"Front Microbiol"},{"key":"2026071507262829000_ciae386-B24","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41467-021-22012-7","article-title":"trans-translation inhibitors bind to a novel site on the ribosome and clear Neisseria gonorrhoeae in vivo","volume":"12","author":"Aron","year":"2021","journal-title":"Nat Commun"},{"key":"2026071507262829000_ciae386-B25","doi-asserted-by":"crossref","first-page":"e00325-18","DOI":"10.1128\/AAC.00325-18","article-title":"Aminomethyl spectinomycins as therapeutics for drug-resistant gonorrhea and Chlamydia coinfections","volume":"62","author":"Butler","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071507262829000_ciae386-B26","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/infdis\/jiab211","article-title":"Preclinical testing of vaccines and therapeutics for gonorrhea in female mouse models of lower and upper reproductive tract infection","volume":"224","author":"Connolly","year":"2021","journal-title":"J Infect Dis"},{"key":"2026071507262829000_ciae386-B27","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1128\/IAI.01155-10","article-title":"Chlamydial infection increases gonococcal colonization in a novel murine coinfection model","volume":"79","author":"Vonck","year":"2011","journal-title":"Infect Immun"},{"key":"2026071507262829000_ciae386-B28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/OLQ.0b013e31820ff9a4","article-title":"The natural history of incident gonococcal infection in adolescent women","volume":"38","author":"Stupiansky","year":"2011","journal-title":"Sex Transm Dis"},{"key":"2026071507262829000_ciae386-B29","author":"Division of Microbiology and Infectious Diseases"},{"key":"2026071507262829000_ciae386-B30","author":"National Institute of Allergy and Infectious Diseases"},{"key":"2026071507262829000_ciae386-B31","author":"Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator"},{"key":"2026071507262829000_ciae386-B32","author":"National Association of County & City Health Officials"},{"key":"2026071507262829000_ciae386-B33","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1097\/OLQ.0000000000001542","article-title":"The implementation of strengthening the US response to resistant gonorrhea in the emergency department setting: successes and lessons learned in 2 jurisdictions","volume":"48","author":"Holderman","year":"2021","journal-title":"Sex Transm Dis"},{"key":"2026071507262829000_ciae386-B34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/OLQ.0000000000001267","article-title":"Critical elements of community engagement to address disparities and related social determinants of health: the Centers of Disease Control and Prevention Community Approaches to Reducing Sexually Transmitted Disease Initiative","volume":"48","author":"Rhodes","year":"2021","journal-title":"Sex Transm Dis"},{"key":"2026071507262829000_ciae386-B35","first-page":"16","article-title":"Promoting community and population health in public health and medicine: a stepwise guide to initiating and conducting community-engaged research","volume":"11","author":"Rhodes","year":"2018","journal-title":"J Health Dispar Res Pract"},{"key":"2026071507262829000_ciae386-B36","author":"US Food and Drug Administration"},{"key":"2026071507262829000_ciae386-B37","author":"US Food and Drug Administration"},{"key":"2026071507262829000_ciae386-B38","author":"European Medicines Agency"},{"key":"2026071507262829000_ciae386-B39","doi-asserted-by":"crossref","first-page":"956462420949126","DOI":"10.1177\/0956462420949126","article-title":"2020 European guideline for the diagnosis and treatment of gonorrhoea in adults","author":"Unemo","year":"2020","journal-title":"Int J STD AIDS"},{"key":"2026071507262829000_ciae386-B40","author":"Pharmaceuticals and Medical Devices Agency"},{"key":"2026071507262829000_ciae386-B41","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1473-3099(19)30116-1","article-title":"Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial","volume":"19","author":"Chen","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026071507262829000_ciae386-B42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study","volume":"46","author":"Hook","year":"2019","journal-title":"Sex Transm Dis"},{"key":"2026071507262829000_ciae386-B43","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/AAC.00400-09","article-title":"AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity","volume":"53","author":"Karlowsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071507262829000_ciae386-B44","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/jac\/dkad181","article-title":"Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin","volume":"78","author":"Nowakowska","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026071507262829000_ciae386-B45","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1128\/AAC.46.10.3118-3124.2002","article-title":"Discovery of a novel and potent class of FabI-directed antibacterial agents","volume":"46","author":"Payne","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071507262829000_ciae386-B46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/OLQ.0000000000001657","article-title":"Systematic review and meta-analysis to estimate the treatment effect and inform a noninferiority margin for a phase 3 noninferiority trial in uncomplicated urogenital gonorrhea","volume":"49","author":"Mitrani-Gold","year":"2022","journal-title":"Sex Transm Dis"},{"key":"2026071507262829000_ciae386-B47","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/cid\/ciz899","article-title":"Development of new antimicrobials for urogenital gonorrhea therapy: clinical trial design considerations","volume":"70","author":"Hook","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026071507262829000_ciae386-B48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae386\/58971157\/ciae386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/1201\/58971157\/ciae386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/1201\/58971157\/ciae386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:26:40Z","timestamp":1784114800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/6\/1201\/7719026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae386","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,15]]},"published":{"date-parts":[[2024,7,24]]}}}